Medtronic To Market Endeavor DES in India

Medtronic has received CE Mark (Conformité Européenne) approval fro the commercial sale of the Endeavor DE Coronary Stent with the Rapid Exchange Delivery System. Endeavor is claimed to be the first Cobalt Alloy drug eluting stent, to be launched in India and 40 other countries outside the US.

"We can now provide physicians and patients with Medtronic's high performance Endeavor DES. Physicians will now have a broader choice among the drug-eluting stents that are available to treat their patients. Endeavor offers a powerful combination of deliverability, efficacy and safety compared with other commercially available stent," said Milind Shah, MD, Medtronic.

Drug-eluting stents have been proven to be superior to traditional bare-metal stents at reducing the rate of repeat procedures due to re-clogging of arteries (restenosis) in patients with coronary artery disease.

According to Dr Jean Fajadet, Clinique Pasteur Unité de Cardiologie Interventionnelle, Toulouse, France and one of the co-principle investigators of the Endeavor II pivotal trial, the results from the Endeavor trials to date have been both comprehensive and positive.

(Ref : Chronicle Pharmabiz dated September 1, 2005)